首页> 美国卫生研究院文献>other >A phase 1 trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer

【2h】

A phase 1 trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer

机译：BKM120（Buparlisib）与氟维司群联合在绝经后女性雌激素受体阳性转移性乳腺癌中的1期试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeThis trial was conducted to determine the maximum tolerated dose (MTD) and preliminary efficacy of buparlisib, an oral pan-class I PI3K inhibitor, plus fulvestrant in postmenopausal women with metastatic estrogen receptor positive breast cancer (ER+BC).

机译：目的进行该试验以确定口服泛I类PI3K抑制剂buparlisib的最大耐受剂量（MTD）和初步疗效，并确定其在具有转移性雌激素受体阳性乳腺癌（ER + BC）的绝经后妇女中具有氟维司群。

著录项

期刊名称 other
作者
Cynthia X. Ma; Jingqin Luo; Michael Naughton; Foluso Ademuyiwa; Rama Suresh; Malachi Griffith; Obi L. Griffith; Zachary L. Skidmore; Nicholas C. Spies; Avinash Ramu; Lee Trani; Timothy Pluard; Gayathri Nagaraj; Shana Thomas; Zhanfang Guo; Jeremy Hoog; Jing Han; Elaine Mardis; Craig Lockhart; Matthew J. Ellis;
展开▼
作者单位

展开▼
年(卷),期 -1(22),7
年度 -1
页码 1583–1591
总页数 19
原文格式 PDF
正文语种
中图分类
关键词
BKM120 (Buparlisib) fulvestrant estrogen receptor positive breast cancer Phase I study phosphatidylinositol-3-kinase (PI3K);

机译：BKM120（Buparlisib）;氟维司群;雌激素受体阳性乳腺癌;I期研究;磷脂酰肌醇3-激酶（PI3K）;

相似文献

外文文献
中文文献
专利

1. A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer [J] . Ma Cynthia X., Luo Jingqin, Naughton Michael, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第7期

机译：绝经后妇女雌激素受体阳性转移性乳腺癌BKM120（Buparlisib）与氟维西坦合用的I期试验
2. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial [J] . Di Leo Angelo, Johnston Stephen, Lee Keun Seok, The lancet oncology . 2018,第1期

机译：Buparlisib Plus氟斯特朗孕妇患有激素受体阳性，Her2阴性，晚期乳腺癌的蛋白质促进剂（Belle-3）：A随机，双盲，安慰剂，第3期试验
3. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, doubleblind, placebo-controlled, phase 3 trial (vol 19, pg 87, 2018) [J] . Di Leo A., Johnston S., Lee K. S. The lancet oncology . 2018,第3期

机译：Buparlisib Plus在绝经后妇女的氟斯特语患有激素受体阳性，Her2阴性，晚期乳腺癌进展（Belle-3）：A随机，双卷麟，安慰剂控制，第3阶段试验（Vol 19，PG 87 ，2018）
4. Estrogen Receptor-Positive Breast Cancer: Traditional Prognostics, Molecular Pathology: A New Breast Cancer Taxonomy and 21st Century Personalized Prognostic and Predictive Assays [C] . Frederick L. Baehner International Symposium on Cancer Metastasis and the Lymphovascular system: Basis for Rational Therapy . 2009

机译：雌激素受体阳性乳腺癌：传统预测，分子病理：新的乳腺癌分类和21世纪个性化预测和预测测定
5. Preferential estrogen receptor beta ligands inhibit proliferation and reduce Bcl-2 expression in Fulvestrant-resistant breast cancer cells. [D] . Ruddy, Samantha C. 2013

机译：优先的雌激素受体β配体抑制耐富夫司特的乳腺癌细胞增殖并降低Bcl-2表达。
6. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal hormone receptor-positive HER2-negative advanced breast cancer (BELLE-2): a randomised double-blind placebo-controlled phase 3 trial [O] . Prof. José Baselga, Prof. Seock-Ah Im, Hiroji Iwata, -1

机译：绝经后激素受体阳性HER2阴性晚期乳腺癌（BELLE-2）的帕帕西布加氟维司群与安慰剂加氟维司群：一项随机双盲安慰剂对照的3期临床试验
7. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial [O] . José Baselga, Seock-Ah Im, Hiroji Iwata, 2017

机译：Buparlisib Plus FulvaStrant与安慰剂加上氟斯特语，激素受体阳性，Her2阴性，晚期乳腺癌（Belle-2）：A随机，双盲，安慰剂控制，第3期试验

A phase 1 trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer

摘要

著录项

相似文献

相关主题

期刊订阅